NCT04012320
Completed
Not Applicable
Efficacy and Safety on the Use of Bisphosphonates in Paediatrics
Centre Hospitalier Universitaire de Nīmes1 site in 1 country99 target enrollmentOctober 31, 2018
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Bone Fragile
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Enrollment
- 99
- Locations
- 1
- Primary Endpoint
- pain frequency
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.
Investigators
Eligibility Criteria
Inclusion Criteria
- •be under 18 years of age
- •have been treated by intravenous bisphosphonates for primary or secondary osteoporosis
Exclusion Criteria
- •be over 18 years of age
Outcomes
Primary Outcomes
pain frequency
Time Frame: 2 years
(never, occasional, regular)
fracture rates
Time Frame: 2 years
(numbers)
bone mineral density
Time Frame: 2 years
(Z-score)
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Examination of utility of bisphosphonate to osteoporosis by ovarian insufficiency after gynecologic cancer treatmentOsteoporosis after gynecologic cancer treatmentJPRN-UMIN000005665Gifu University50
Recruiting
Phase 3
Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric SurgeryBone LossNCT04922333Wake Forest University Health Sciences200
Unknown
Not Applicable
Radiographic Influences of Bisphosphonate Treatment on FemurFemur FractureNCT01969279Tomidahama Hospital100
Completed
Phase 4
Bisphosphonate Therapy for Osteogenesis ImperfectaOsteogenesis ImperfectaOsteoporosisPaget Disease of BoneNCT00159419Indiana University School of Medicine18
Completed
Phase 4
Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast CancerProstate CancerBreast CancerBone MetastasisNCT00334139Novartis Pharmaceuticals411